The Claim

In patients with coronary artery disease undergoing percutaneous coronary intervention, baseline high-sensitivity C-reactive protein levels above 3 mg/L are associated with a 4.9% rate of major adverse cardiac and cerebrovascular events within one year, while levels below 2 mg/L are associated with a 2.6% rate of such events.

Source: Clinical impact of systemic inflammation across different high-sensitivity C-reactive protein cutoffs in patients undergoing percutaneous coronary intervention.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
52score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Correlation
1 study reviewed
In plain English

Patients with coronary artery disease who have higher levels of a blood marker called high-sensitivity C-reactive protein before undergoing heart procedure are more likely to experience a heart attack, stroke, or death within one year than those with lower levels of this marker.

See the scientific wording

In patients with coronary artery disease undergoing percutaneous coronary intervention, baseline high-sensitivity C-reactive protein levels above 3 mg/L are associated with a 4.9% rate of major adverse cardiac and cerebrovascular events within one year, compared to 2.6% in those with levels below 2 mg/L, indicating that systemic inflammation, as measured by hsCRP, correlates with increased risk of death, heart attack, or stroke after the procedure.

Why this might work

High levels of a blood protein called hsCRP signal widespread inflammation in the body, which activates immune cells inside artery walls. These cells break down the protective covering of fatty plaques, making them more likely to rupture. When a plaque ruptures, it triggers blood clotting that can block the artery, causing a heart attack, stroke, or death.

Verified mechanismbased on 1 study

What the research says

1 study
  1. Study: Clinical impact of systemic inflammation across different high-sensitivity C-reactive protein cutoffs in patients undergoing percutaneous coronary intervention.

    The study found that heart patients with higher levels of a blood marker called hsCRP (above 3 mg/L) were more likely to have a heart attack, stroke, or die within a year than those with lower levels (below 2 mg/L), which is exactly what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.